InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Friday morning. The brokerage issued a sell rating on the stock.

A number of other research analysts have also commented on the company. Lake Street Capital assumed coverage on InspireMD in a report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Up 0.7 %

NSPR stock opened at $3.00 on Friday. The firm has a 50 day moving average of $2.69 and a two-hundred day moving average of $2.69. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The company has a market capitalization of $78.25 million, a price-to-earnings ratio of -4.00 and a beta of 0.98.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The firm had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the prior year, the company posted ($0.15) earnings per share. On average, research analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD as of its most recent SEC filing. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.